Medical sensor system for detecting a feature in a body

• US 9,538,942 B2
• Filed: 09/07/2011
• Issued: 01/10/2017
• Est. Priority Date: 09/28/2010
• Status: Active Grant

• Current Assignee: Biotronik SE & Company KG
• Original Assignee: Biotronik SE & Company KG
• Inventors: Ulmer, Jens
• Primary Examiner(s): Natnithithadha, Navin
• Assistant Examiner(s): MESSERSMITH, ERIC J
• Application Number:
  US13/226,522
• Publication Number:
  US 20120078068A1
• Time in Patent Office: 1,952 Days
• Field of Search: 600/302, 600/365, 600/347
• US Class Current: 1/1
• CPC Class Codes: A61B 2560/0443 Modular apparatus
• CPC Class Codes: A61B 2562/12 Manufacturing methods specially adapted for producing sensors for in-vivo measurements
• CPC Class Codes: A61B 5/0031 Implanted circuitry
• CPC Class Codes: A61B 5/0515 Magnetic particle imaging
• CPC Class Codes: A61B 5/055 involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/14735 comprising an immobilised reagent
• CPC Class Codes: A61B 5/681 Wristwatch-type devices
• CPC Class Codes: A61B 5/6846 specially adapted to be brought in contact with an internal body part, i.e. invasive
• CPC Class Codes: A61B 5/6898 Portable consumer electronic devices, e.g. music players, telephones, tablet computers

Abstract

The invention relates to a medical sensor system (10a/10c) for detecting a feature (12a/12c) in a human or animal body (14a/14c), including a signal pick-up unit (16a/16c), which can be implanted in the animal and/or human body (14a/14c), and a signal processing unit (18a/18c), which is spatially separated from the signal pick-up unit (16a/16c) and which includes a transmitter (20a/20c) and a receiver (22a/22c). The transmitter (20a/20c) emits an alternating magnetic field (24a/24c) to act on the signal pick-up unit (16a/16c), and the receiver (22a/22c) receives a response signal (26a/26c) of the signal pick-up unit (16a/16c), which is generated by the magnetic interaction of the alternating magnetic field (24a/24c) with the signal pick-up unit (16a/16c).

Claims

1. A medical sensor system for detecting a feature in a body, the system including:

a. a signal pick-up unit configured to be implanted within the body, the signal pick-up unit including;

(1) a magnetic nanoparticle having a coating consisting essentially of a receptor, the receptor being configured to competitively bind to;

(a) an analyte, and

(b) an analog of the analyte,

as a function of a concentration of the analyte;

(2) at least one polymer of monomers from;

(a) N-isopropylacrylamide,

(b) N,N-diethylacrylamide,

(c) methyl vinyl ether,

(d) N-vinylcaprolactam,

(e) ethylene oxide-co-propylene oxide,

(f) lactic acid,

(g) glycolic acid,

(h) trimethylcarbonate,

(i) acrylate,

(j) methacrylate,

(k) hydroxyethyl-metacrylate,

(l) vinyl ester;

b. a signal processing unit;

(1) spatially separated from the signal pick-up unit, and

(2) including;

(a) a transmitter configured to emit an alternating magnetic field which acts on the signal pick-up unit to generate a response signal from the signal pick-up unit, and

(b) a receiver configured to receive the response signal of the signal pick-up unit.

2. The medical sensor system of claim 1 wherein the signal pick-up unit is configured to generate a response signal dependent on the concentration of a glucose analyte.

3. The medical sensor system of claim 2 wherein the analog includes dextran.

4. The medical sensor system of claim 2 wherein the receptor includes Concanavalin A.

5. The medical sensor system of claim 1 wherein the receptor includes Concanavalin A.

6. The medical sensor system of claim 1 wherein the analog is at least partially formed of a hydrogel wherein the magnetic nanoparticle is disposed.

7. The medical sensor system of claim 6 wherein:

a. the magnetic nanoparticle, and

b. the analog,

are at least partially surrounded by a biodegradable layer.

8. The medical sensor system of claim 1 wherein the analog is configured to degrade upon application of an alternating magnetic field to the signal pick-up unit.

9. The medical sensor system of claim 7 wherein biodegradability is thermally activated.

10. The medical sensor system of claim 7 wherein biodegradability is activated by application of an alternating magnetic field.

11. The medical sensor system of claim 1 wherein the analog is at least partially formed of a hydrogel.

23. The medical sensor system of claim 6 wherein the receptor is configured to release from the analog, and thus from the hydrogel, in the presence of the analyte.

12. A method for detecting an analyte in a body using a sensor system, the system including:

A. a signal pick-up unit configured to be implanted within the body, the signal pick-up unit including;

I. a magnetic nanoparticle,

II. a hydrogel, the hydrogel including an analog of the analyte, and

III. a coating on the nanoparticle, the coating consisting essentially of a receptor of the analyte and analog,

B. a signal processing unit spatially separated from the signal pick-up unit, the signal processing unit including a transmitter and a receiver;

wherein the method includes the steps of;

a. transmitting an alternating magnetic field from the transmitter, the magnetic field acting on the signal pick-up unit to generate a response signal therefrom;

b. receiving the response signal of the signal pick-up unit at the receiver.

13. The method of claim 12 wherein the signal processing unit is situated outside the body.

14. The method of claim 12 wherein the magnetic nanoparticle is configured to exhibit a magnetic susceptibility as the response signal, the susceptibility being dependent on the concentration of an analyte within the body.

15. The method of claim 12 further including the step of supplying an alternating magnetic field to the signal pick-up unit, the magnetic field being configured to induce biodegradation of the signal pick-up unit.

18. The medical sensor system of claim 12 wherein the hydrogel includes at least one polymer of monomers from:

a. N-isopropylacrylamide,

b. N,N-diethylacrylamide,

c. methyl vinyl ether,

d. N-vinylcaprolactam,

e. ethylene oxide-co-propylene oxide,

f. lactic acid,

g. glycolic acid,

h. trimethylcarbonate,

i. acrylate,

j. methacrylate,

k. hydroxyethyl-metacrylate,

l. vinyl ester.

24. The method of claim 12 wherein the receptor is configured to preferentially bind to the analyte, whereby the nanoparticle and the receptor thereon release from the analog of the hydrogel in the presence of the analyte.

16. A medical sensor system for detecting an analyte in a body, the system including:

a. a signal pick-up unit configured to be implanted within the body, the signal pick-up unit including

(1) a hydrogel, and

(2) a magnetic nanoparticle being configured to exhibit a magnetic property dependent on the concentration of the analyte within the body,

(3) a coating on the magnetic nanoparticle, the coating consisting essentially of a receptor of;

(a) an analyte, and

(b) an analog of the analyte,

whereby the magnetic nanoparticle may reversibly bind to the analyte and analog via the receptor;

b. a signal processing unit;

(1) situated outside the body, and

(2) including;

(a) a transmitter configured to emit an alternating magnetic field, and

(b) a receiver configured to receive a response signal from at least the magnetic nanoparticle of the signal pick-up unit, the response signal being induced by the alternating magnetic field.

17. The medical sensor system of claim 16 wherein the magnetic nanoparticle is configured to bind to at least one of:

a. the hydrogel, and

b. the analyte,

in dependence on the concentration of the analyte within the body.

19. The medical sensor system of claim 16 wherein the hydrogel is at least partially formed of the analog.

20. The medical sensor system of claim 19 wherein the hydrogel includes at least one polymer of monomers from:

a. N-isopropylacrylamide,

b. N,N-diethylacrylamide,

c. methyl vinyl ether,

d. N-vinylcaprolactam,

e. ethylene oxide-co-propylene oxide,

f. lactic acid,

g. glycolic acid,

h. trimethylcarbonate,

i. acrylate,

j. methacrylate,

k. hydroxyethyl-metacrylate,

l. vinyl ester.

21. The medical sensor system of claim 16 wherein the receptor includes Concanavalin A therein.

22. The medical sensor system of claim 16 wherein the signal pick-up unit is configured to biodegrade when an alternating magnetic field is supplied thereto.

25. The method of claim 16 wherein:

a. the hydrogel bears the analog thereon, and

b. the receptor is configured to preferentially bind to the analyte,

whereby the nanoparticle and the receptor thereon release from the analog of the hydrogel in the presence of the analyte.